YARROW BIOSCIENCE, INC. Restructuring and Related Cost, Expected Number of Positions Eliminated
YARROW BIOSCIENCE, INC. (YARW) reported Restructuring and Related Cost, Expected Number of Positions Eliminated of 70 employee for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated · last filed 2021-11-10
- 2021-09-30: Restructuring and Related Cost, Expected Number of Positions Eliminated 9 month 70.00 employee.
| Period end | Restructuring and Related Cost, Expected Number of Positions Eliminated 9 month |
|---|---|
| 2021-09-30 | 70.00 employee 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |